Harrow Inc
HROW
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.53B
Close$
$13.51
67.3% downside
Current Fair Value
67.3% downsideOvervalued by 67.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.53 Billion |
|---|---|
| Enterprise Value | $1.74 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.14 |
| Beta | 0.25 |
| Outstanding Shares | 37,350,401 |
Return
| Return on Equity | -244.91% |
|---|---|
| Return on Assets | -8.93% |
| Return on Invested Capital | -7.37% |
Valuation & Multiples
| P/E Ratio | -41.26 |
|---|---|
| PEG | 9.26 |
| Price to Sales | 5.9 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 6.33 |
| Enterprise Value to EBIT | -75.23 |
| Enterprise Value to Net Income | -47 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | 19.79 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
$70.35 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$0.22
Average shareholder expectationRevenue Estimate
$100.37 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3717▼ 13.38% |
|---|---|
| Total Calls | 1,334,800▲ 23.51% |
| Total Puts | 496,100▼ 9.19% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 62.69%▲ 4.46% |
|---|---|
| Total Invested | $960.42M▲ 27.16% |
| Investors Holding | 232▲ 6.00% |
ESG Score
No data
About Harrow Health Inc
125 employeesHarrow Health, Inc. owns a portfolio of ophthalmic pharmaceutical businesses, including ImprimisRx, the nation's leading ophthalmology outsourcing facility and pharmaceutical compounding business. The company holds large equity positions...